AIM The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial
Fibrillation” provides recommendations to guide clinicians in the treatment of patients with …

It is well established that direct oral anticoagulants (DOACs) are the cornerstone of
anticoagulant strategy in atrial fibrillation (AF) and venous thromboembolism (VTE) and …

Background Apixaban and rivaroxaban are increasingly used for thromboembolism
prophylaxis in patients with non‐valvular atrial fibrillation (NVAF) and commonly in patients …

Despite evolving evidence, the use of direct oral anticoagulants (DOACs) in patients with
extremes of body weight remains controversial. This study aimed to measure the impact of …

Phase III clinical trials for individual direct oral anticoagulants (DOACs) contained a limited
representation of subjects with abnormal body weight, which were mostly limited to a BMI> …

The use of the direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban
(DOACs) offers some major advantages over warfarin and other vitamin K antagonists …

The global prevalence of obesity has more than doubled over the past four decades,
currently affecting more than a billion individuals. Beyond its recognition as a high-risk …

Summary Background Direct oral anticoagulants (DOACs) are effective and safe alternatives
to warfarin for stroke prophylaxis for atrial fibrillation (AF). Whether this extends to patients at …

Introduction The clinical outcomes of direct oral anticoagulant (DOAC) dosage regimens in
morbid obesity are uncertain due to limited clinical evidence. This study seeks to bridge this …

Bariatric surgery has emerged as a therapy for obesity and the associated comorbidities.
Obesity has been shown to be a risk factor for atrial fibrillation as well as venous …